### Analysis:

Johnson & Johnson (JNJ) reported strong Q2 2013 results, with significant growth in its pharmaceutical segment, driven by new product launches and market share gains. The company's consumer segment also showed positive growth, particularly in the U.S. OTC market. However, the company's medical devices and diagnostics (MD&D) segment faced challenges due to pricing pressures and macroeconomic factors.

### Key Points:

1. **Pharmaceutical Segment:**
   - **Sales:** $7.0 billion, up 11.7% year-over-year (YoY).
   - **Earnings:** $3.8 billion, up 17.7% YoY.
   - **Notable Products:** ZYTIGA, XARELTO, and INCIVO.
   - **Pipeline:** Positive developments in immunology, infectious diseases, and oncology.

2. **Medical Devices and Diagnostics Segment:**
   - **Sales:** $7.2 billion, up 12% YoY.
   - **Earnings:** $2.1 billion, up 7.7% YoY.
   - **Notable Products:** Biosense Webster, ENT, and Vision Care.
   - **Challenges:** Pricing pressures and macroeconomic factors.

3. **Consumer Segment:**
   - **Sales:** $3.7 billion, up 1.1% YoY.
   - **Earnings:** $1.0 billion, up 1.7% YoY.
   - **Notable Products:** Baby Care, Oral Care, and Women's Health.
   - **Challenges:** Remediation efforts for OTC products and divestitures.

### Short-Term Impact:

- **Pharmaceutical Segment:** Positive short-term impact due to strong sales and earnings growth.
- **Medical Devices and Diagnostics Segment:** Mixed short-term impact due to pricing pressures and macroeconomic factors.
- **Consumer Segment:** Positive short-term impact due to growth in U.S. OTC market and strong consumer brands.

### Conclusion:

Overall, the short-term impact on JNJ's stock price is likely to be positive, driven by strong Q2 earnings and positive guidance for the rest of the year. The company's focus on innovation, market share growth, and strategic acquisitions positions it well for future growth. However, challenges in the MD&D segment and macroeconomic factors may temper short-term optimism.

**Rating: 1**